Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

RxSight (RXST) EBIT (2020 - 2026)

RxSight filings provide 6 years of EBIT readings, the most recent being $28.7 million for Q4 2025.

  • On a quarterly basis, EBIT rose 27.65% to $28.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.2 million, a 41.9% decrease, with the full-year FY2025 number at -$8.2 million, down 41.86% from a year prior.
  • EBIT hit $28.7 million in Q4 2025 for RxSight, up from -$12.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $29.0 million in Q4 2023 to a low of -$16.6 million in Q1 2022.
  • Median EBIT over the past 5 years was -$12.8 million (2023), compared with a mean of -$7.0 million.
  • Biggest five-year swings in EBIT: crashed 76.62% in 2021 and later soared 293.66% in 2023.
  • RxSight's EBIT stood at -$14.7 million in 2021, then decreased by 2.23% to -$15.0 million in 2022, then soared by 293.66% to $29.0 million in 2023, then fell by 22.58% to $22.5 million in 2024, then increased by 27.65% to $28.7 million in 2025.
  • The last three reported values for EBIT were $28.7 million (Q4 2025), -$12.2 million (Q3 2025), and -$14.0 million (Q2 2025) per Business Quant data.